Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer.

Details

Ressource 1Download: pmid26856369.pdf (1571.56 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_97EC7850B286
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer.
Journal
Scientific reports
Author(s)
Dupouy D.G., Ciftlik A.T., Fiche M., Heintze D., Bisig B., de Leval L., Gijs M.A.
ISSN
2045-2322 (Electronic)
ISSN-L
2045-2322
Publication state
Published
Issued date
09/02/2016
Peer-reviewed
Oui
Volume
6
Pages
20277
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Publication types: Journal Article ; Research Support, Non-U.S. Gov't

Abstract
Chromogenic immunohistochemistry (IHC) is omnipresent in cancer diagnosis, but has also been criticized for its technical limit in quantifying the level of protein expression on tissue sections, thus potentially masking clinically relevant data. Shifting from qualitative to quantitative, immunofluorescence (IF) has recently gained attention, yet the question of how precisely IF can quantify antigen expression remains unanswered, regarding in particular its technical limitations and applicability to multiple markers. Here we introduce microfluidic precision IF, which accurately quantifies the target expression level in a continuous scale based on microfluidic IF staining of standard tissue sections and low-complexity automated image analysis. We show that the level of HER2 protein expression, as continuously quantified using microfluidic precision IF in 25 breast cancer cases, including several cases with equivocal IHC result, can predict the number of HER2 gene copies as assessed by fluorescence in situ hybridization (FISH). Finally, we demonstrate that the working principle of this technology is not restricted to HER2 but can be extended to other biomarkers. We anticipate that our method has the potential of providing automated, fast and high-quality quantitative in situ biomarker data using low-cost immunofluorescence assays, as increasingly required in the era of individually tailored cancer therapy.

Keywords
Biomarkers, Tumor/genetics, Biomarkers, Tumor/metabolism, Breast Neoplasms/genetics, Breast Neoplasms/metabolism, Female, Fluorescent Antibody Technique, Gene Amplification, Humans, In Situ Hybridization, Fluorescence, Microfluidics/instrumentation, Microfluidics/methods, Pilot Projects, Receptor, ErbB-2/genetics, Receptor, ErbB-2/metabolism
Pubmed
Web of science
Open Access
Yes
Create date
20/02/2016 15:37
Last modification date
20/08/2019 14:59
Usage data